Citi Sticks to Their Buy Rating for Danaher (DHR)
Citi analyst Patrick B Donnelly maintained a Buy rating on Danaher on January 2. The company’s shares closed last Friday at $230.40.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
B Donnelly covers the Healthcare sector, focusing on stocks such as Exact Sciences, Illumina, and Guardant Health. According to TipRanks, B Donnelly has an average return of 4.3% and a 49.68% success rate on recommended stocks.
Danaher has an analyst consensus of Strong Buy, with a price target consensus of $256.13, which is an 11.17% upside from current levels. In a report released on December 18, KeyBanc also assigned a Buy rating to the stock with a $310.00 price target.
Based on Danaher’s latest earnings release for the quarter ending September 26, the company reported a quarterly revenue of $6.05 billion and a net profit of $908 million. In comparison, last year the company earned a revenue of $5.8 billion and had a net profit of $818 million
Based on the recent corporate insider activity of 57 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of DHR in relation to earlier this year. Most recently, in November 2025, Mitchell Rales, the Chairman of Exec. Committee of DHR sold 40,625.00 shares for a total of $9,359,066.67.
Read More on DHR:
